Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00483262 · OUTCOME

Progression-Free Survival

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma · Source last updated 2013-11-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
month
Interval / dispersion
95% Confidence Interval
Time frame
10 months

What was measured

Median time to progression or death

Groups in this outcome

CCI779 PFS Phase I

Progression-free survival results from the phase I part of the phase I/II CCI779 with velcade study.

CCI779 PFS Phase II

Progression-free survival results from the phase II part of the phase I/II CCI779 with velcade study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CCI779 PFS Phase I20
CCI779 PFS Phase II43

Reported measurements

Source class 1
Values in month · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
CCI779 PFS Phase I5.7Not reported1.59.2Not reported
CCI779 PFS Phase II5.0Not reported3.96.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.5
        upper Limit
        9.2
        value
        5.7
      2. group Id
        OG001
        lower Limit
        3.9
        upper Limit
        6.4
        value
        5.0
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    2. group Id
      OG001
      value
      43
    units
    Participants
description
Median time to progression or death
dispersion Type
95% Confidence Interval
groups
  1. description
    Progression-free survival results from the phase I part of the phase I/II CCI779 with velcade study.
    id
    OG000
    title
    CCI779 PFS Phase I
  2. description
    Progression-free survival results from the phase II part of the phase I/II CCI779 with velcade study.
    id
    OG001
    title
    CCI779 PFS Phase II
param Type
MEDIAN
reporting Status
POSTED
time Frame
10 months
title
Progression-Free Survival
type
SECONDARY
unit Of Measure
month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice